KalVista Pharmaceuticals (KALV) Stock Chart & Stock Price History $8.76 -0.07 (-0.79%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KalVista Pharmaceuticals Stock Price Performance 5 Day Performance+4.78%1 Month Performance-13.01%3 Month Performance-7.40%6 Month Performance-24.16%Year-To-Date Performance-28.49%1 Year Performance-25.00% Receive KALV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. KALV Stock Chart for Thursday, December, 26, 2024 KALV Chart by TradingView KalVista Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/25/2024$8.76$8.76$8.82$8.48125,256 shs$432.90 million12/24/2024$8.83$8.76-0.79%$8.82$8.48125,256 shs$432.90 million12/23/2024$8.36$8.83+5.62%$8.86$8.15848,899 shs$413.13 million12/20/2024$8.09$8.36+3.34%$8.55$7.971.01 million shs$413.13 million12/19/2024$8.46$8.09-4.37%$8.70$8.07408,784 shs$399.79 million12/18/2024$8.65$8.46-2.20%$9.30$8.25770,962 shs$418.08 million Get the Latest News and Ratings for KALV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/17/2024$8.95$8.65-3.35%$9.07$8.52377,826 shs$427.47 million12/16/2024$8.69$8.95+2.99%$9.22$8.61645,036 shs$442.29 million12/13/2024$8.75$8.69-0.63%$8.91$8.48412,771 shs$429.46 million12/12/2024$9.09$8.75-3.80%$9.15$8.50377,157 shs$432.16 million12/11/2024$9.44$9.09-3.71%$9.57$9.07219,045 shs$449.23 million12/10/2024$9.34$9.44+1.07%$9.59$9.13247,561 shs$466.53 million12/09/2024$9.81$9.34-4.79%$9.87$9.32318,003 shs$461.58 million12/06/2024$9.06$9.81+8.34%$9.86$8.98362,034 shs$423.99 million12/05/2024$9.46$9.06-4.28%$9.84$9.00334,989 shs$391.36 million12/04/2024$9.73$9.46-2.77%$10.20$9.35345,543 shs$408.81 million12/03/2024$10.27$9.73-5.26%$10.20$9.71216,674 shs$443.82 million12/02/2024$10.06$10.27+2.09%$10.48$9.89298,106 shs$443.87 million11/29/2024$10.09$10.06-0.30%$10.21$9.83302,300 shs$434.79 million11/28/2024$10.09$10.09$10.27$9.95162,899 shs$436.09 million11/27/2024$9.98$10.09+1.10%$10.27$9.95162,899 shs$436.09 million11/26/2024$10.07$9.98-0.89%$10.07$9.68235,648 shs$431.34 million11/25/2024$10.15$10.07-0.79%$10.44$9.97973,231 shs$435.23 million Related Companies EVO Stock Price Chart KNSA Stock Price Chart PRAX Stock Price Chart RCUS Stock Price Chart IMCR Stock Price Chart NRIX Stock Price Chart TVTX Stock Price Chart OCUL Stock Price Chart SEPN Stock Price Chart DAWN Stock Price Chart Receive KALV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:KALV) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
